Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial Meeting Abstract
| Authors: | Albiges, L.; Rodriguez, L. M.; Kim, S. W.; Im, S. A.; Carcereny, E.; Rha, S. Y.; Tran, B.; Oliveira, J.; Maroto-Rey, P.; Su, W. C.; Voskoboynik, M.; Rodriguez-Vida, A.; Costa, L.; Ascierto, P. A.; Molla, M. A. I.; Wang, Y.; Gainer, S. D.; Subramaniam, D. S.; Voss, M. H. |
| Abstract Title: | Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300241 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.107 |
| Notes: | Meeting Abstract: 107 -- This meeting was also held virtually -- Source: Wos |
